Home > Press > Keystone Nano selected as a top scoring company by NCI investor review panel
Abstract:
Keystone Nano is pleased to announce that it has been selected for additional support from the National Cancer Institute of the National Institutes of Health. After a careful and competitive review by a National Cancer Institute (NCI) panel looking for leading investment opportunities among Small Business Innovation Research (SBIR) awardees, Keystone Nano was selected as a top scoring applicant and has been awarded support for business development.
“Keystone Nano is pleased to be selected as one of the leading NCI SBIR funded companies of 2016. We are grateful that NCI has recognized the value of our work and the approach we are taking. This selection further validates the commercial opportunities associated with our products and technologies”, remarked Mr. James Sharpe, Keystone Nano’s Vice President of Business Development.
####
About Keystone Nano
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing Ceramide NanoLiposome for the treatment of cancer, and is developing additional products using NanoJackets, non-toxic calcium phosphate nanoparticles that can be targeted to specific cell types and can deliver a wide range of materials from classical chemotherapeutics to siRNA and mRNA. The Company’s product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
For more information about Keystone Nano, our products and our technology, visit our website www.keystonenano.com, or contact Jeff Sirianni at .
For more information, please click here
Contacts:
Jeff Sirianni at
t: @Keystonenano
Copyright © Keystone Nano
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Researchers develop artificial building blocks of life March 8th, 2024
Cancer
Super-efficient laser light-induced detection of cancer cell-derived nanoparticles: Skipping ultracentrifugation, detection time reduced from hours to minutes! October 6th, 2023
The medicine of the future could be artificial life forms October 6th, 2023
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records
'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024
Nanobiotechnology
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||